A meeting of Orphan Drug pioneers & rare disease experts to drive innovation

In Uncategorized by Matt TurnerLeave a Comment

World Orphan Drug Congress Europe 2011 logo

 

 

In a previous post, I outlined the changes being made to the 3rd Annual World Orphan Drug Congress and the fact that 3 focused tracks will be taking place simultaneously that focus on:

More dedicated content means more high level and pioneering speakers to shape the industry conversations and drive the debate. A truly unrivalled speaker faculty of 60+ pioneers from industry, patient groups, rare disease networks, payers, policy makers and academia will lead the debate. A notable selection of speakers include:

 

Emil Kakkis, Founder, Kakkis EveryLife Foundation; President & CEO, Ultragenyx
Yann Le Cam, CEO, EURORDIS; Vice-Chair, EUCERD
Michael Scott, Chairman of the Board of Directors, NORD
Ruxandra Draghia-Akli, Director of the Health Directorate at the Research DG, European Commission
Richard BergstrÓ§m, Director General, European Federation of Industries & Associations (EFPIA)
Geoffrey McDonough, President & CEO, Swedish Orphan Biovitrum
Stuart Peltz, CEO, PTC Therapeutics
Carlo Incerti, Head of Global Medical Affairs, Genzyme
Jeannie Joughin, VP Business Development, CSL Behring
Jeremy Springhorn, VP Corporate Strategy & Business Development, Alexion Pharmaceuticals
Peter Mueller, EVP Global R&D & CSO, Vertex Pharmaceuticals
Colin Broom, VP, CSO, Viropharma
Theresa Heggie, Senior Vice President of Global Commercial Operations, Shire HGT
Hans Schikan, CEO, Prosensa
Elizabeth White, AVP, Rare Disease Specialty Care Commercial Development, Pfizer
Corinne Savill, Global Head Pricing & Reimbursement, Novartis
Robert Mattaliano Group VP – Biologic Development, Genzyme
Michel Pairet, SVP Head of Venture Fund, Boehringer-Ingelheim
Per Nilsson, VP Head of Strategic Clinical Development, Actelion
Massimo Boriero, VP Europe, Aegerion Pharmaceuticals
Francis Pang, Senior Director, Global Health Economics and Outcomes Research, Shire HGT
Remco de Vrueh, Founder, Rare Disease Matters
Ad Schuurman, Head of Business Contact Centre & International Affairs, CVZ; President, MEDEV
Francois Meyer, Advisor to the President, International Affairs, HAS
Domenica Taruscio, Director, Italian Ministry of Health
Paolo Daniele Siviero, Head of Economic Strategy & Pharmaceutical Policy, Italian Medicines Agency
Anna Bucsics, Department Head, Main Association of Austrian Security Institutions (HVB)
Ri De Ridder, Director General, Healthcare Department, National Institute for Health & Disability Insurance
Francis Arickx, Advisor, National Institute for Health & Disability Insurance

 

For full information about the 3 content streams and the specific presentations within them delivered by the speakers above, you can now download the brochure here.

Leave a Comment

Current ye@r *